Top Markets
Coin of the day
Damora Therapeutics, Inc. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA
株式のランク #6696
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering... Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
株価
$30.90
最終同期: 2026-08-27
時価総額
$1.90B
変化(1日)
1.68%
変化(1年)
859.63%
US
取引 Damora Therapeutics, Inc. (DMRA)

カテゴリー

Damora Therapeutics, Inc.(DMRA)の配当利回りの履歴
Damora Therapeutics, Inc.(銘柄コード: DMRA)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Damora Therapeutics, Inc.(DMRA)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)